Background The current available evidence on the management of metastatic renal cell
cancer (mRCC) in real life is scarce in our environment. We present a summary of the …

Background Real‐world data describing outcomes of treatment among metastatic renal cell
carcinoma (mRCC) patients are limited and heterogeneous. Aim RENSUR3 registry study …

Background Patient characteristics and survival outcomes in randomized trials may be
different from those in real-life clinical practice. The objective of this study was to describe …

20 Background: The results of the 5-year overall survival (OS) in patients with metastatic
renal cell carcinoma (mRCC) has been reported rarely. The aim of the RENSUR5 registry …

Simple Summary The management of metastatic renal cell carcinoma (mRCC) represents a
clinical challenge. Progression or toxicity may occur during first-line treatments and many …

Aims and scope The last 7 years have seen the treatment landscape for metastatic renal cell
carcinoma (mRCC) dramatically change as the understanding of the molecular background …

389 Background: This retrospective register study assessed OS in all mRCC patients in
Sweden diagnosed before (2000–2005) and after (2006–2008) the introduction of targeted …

Background Before the era of targeted therapies, cytokines were the main therapy for
metastatic renal cell carcinoma (mRCC). Our aim was to analyze the changes in treatments …

Background/Aim: Since the advent of targeted therapeutics, paradigms in metastatic renal
cell carcinoma (mRCC) treatment have changed. We investigated if efficacy and safety data …

Background The 5-year overall survival (OS) of patients with metastatic renal cell carcinoma
(mRCC) has been rarely reported. The aim of the RENSUR5 registry study was to obtain …